Mir-Bonafé J M, Vilalta A, Alarcón I, Carrera C, Puig S, Malvehy J, Rull R, Bennàssar A
Servicio de Dermatología, Unidad de Melanoma, Hospital Clínic, Universidad de Barcelona, Barcelona, España.
Servicio de Dermatología, Unidad de Melanoma, Hospital Clínic, Universidad de Barcelona, Barcelona, España.
Actas Dermosifiliogr. 2015 May;106(4):285-91. doi: 10.1016/j.ad.2014.10.007. Epub 2014 Dec 12.
Electrochemotherapy is indicated for the treatment of unresectable cutaneous and subcutaneous tumors. The technique involves the synergistic use of electroporation of cell membranes to increase the cytotoxicity of anticancer drugs delivered to the tumor cells. The aim of this study was to analyze the clinical effectiveness and safety of electrochemotherapy in the treatment of unresectable locoregional recurrent or metastatic melanomas.
We studied 31 patients treated between January 2007 and December 2012. The European Standard Operating Procedures of Electrochemotherapy (ESOPE) were applied in all cases. Treatment response was analyzed as overall patient response (mean response based on results for all lesions treated in a given patient).
Response was classified as partial in 49% of patients and complete in 23%. At 1 year, the level of response achieved had been maintained in 17 patients. Disease progression was observed in 28% of the series. Immediate local complications (pain, swelling, erythema) were mild and resolved within 48hours in most cases. Eight patients developed subsequent local complications, such as ulcers and secondary infections associated with necrosis of the lesions. These complications were brought under control with topical treatments.
Electrochemotherapy is a very effective, safe, and efficient treatment for advanced locoregional disease in patients with unresectable melanoma lesions.
电化学疗法适用于治疗无法切除的皮肤和皮下肿瘤。该技术涉及协同利用细胞膜电穿孔来增强递送至肿瘤细胞的抗癌药物的细胞毒性。本研究的目的是分析电化学疗法治疗无法切除的局部区域复发或转移性黑色素瘤的临床疗效和安全性。
我们研究了2007年1月至2012年12月期间接受治疗的31例患者。所有病例均采用欧洲电化学疗法标准操作程序（ESOPE）。治疗反应分析为总体患者反应（基于给定患者所有治疗病变结果的平均反应）。
49%的患者反应分类为部分缓解，23%为完全缓解。1年时，17例患者维持了所达到的反应水平。该系列中28%观察到疾病进展。即刻局部并发症（疼痛、肿胀、红斑）较轻，大多数病例在48小时内缓解。8例患者出现后续局部并发症，如溃疡和与病变坏死相关的继发感染。这些并发症通过局部治疗得到控制。
电化学疗法是治疗无法切除黑色素瘤病变的晚期局部区域疾病的一种非常有效、安全且高效的治疗方法。
